THIS STORY HAS BEEN FORMATTED FOR EASY PRINTING
AROUND THE REGION

Vertex Pharmaceuticals loss widens

Associated Press / February 10, 2009
  • Email|
  • Print|
  • Single Page|
  • |
Text size +

Cambridge-based Vertex Pharmaceuticals Inc. said yesterday its fourth-quarter loss widened as development costs increased and revenue dropped sharply.

Vertex posted a loss of $142.3 million, or 96 cents per share, in the quarter. That compares with a loss of $85.8 million, or 66 cents per share, a year earlier. Revenue shrank 36 percent to $32.8 million from $51 million as both royalty revenue and collaborative revenue fell. Excluding stock-based compensation and other one-time items, Vertex reported a loss of $126.9 million, or 85 cents per share, compared with $72.8 million, or 56 cents per share in the fourth quarter of 2007. Analysts expected a loss of 93 cents per share and $35.9 million in revenue, according to a survey by Thomson Reuters.

The company said its adjusted loss widened to $397.5 million, or $2.83 per share, in 2008, from $324.8 million, or $2.52 per share in 2007. Vertex expects similar losses in 2009.

. . . VRTX . . .
Vertex Pharmaceuticals
YESTERDAY
Close$33.53
Change-$1.47
52-WEEK
High$35.97
Low$13.84

  • Email
  • Email
  • Print
  • Print
  • Single page
  • Single page
  • Reprints
  • Reprints
  • Share
  • Share
  • Comment
  • Comment
 
  • Share on DiggShare on Digg
  • Tag with Del.icio.us Save this article
  • powered by Del.icio.us
Your Name Your e-mail address (for return address purposes) E-mail address of recipients (separate multiple addresses with commas) Name and both e-mail fields are required.
Message (optional)
Disclaimer: Boston.com does not share this information or keep it permanently, as it is for the sole purpose of sending this one time e-mail.